Cargando…
Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
Autores principales: | Halford, Sarah, Wan, Susan, Dragoni, Ilaria, Silvester, Julie, Nazarov, Bobojon, Anthony, Daniel, Anthony, Suzie, Ladds, Emma, Norrie, John, Dhaliwal, Kevin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022056/ https://www.ncbi.nlm.nih.gov/pubmed/35449061 http://dx.doi.org/10.1186/s13063-022-06266-0 |
Ejemplares similares
-
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
por: Halford, Sarah, et al.
Publicado: (2021) -
Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020) -
Spectral Analysis of Input Spike Trains by Spike-Timing-Dependent Plasticity
por: Gilson, Matthieu, et al.
Publicado: (2012) -
Palmitoylation of the cysteine-rich endodomain of the SARS–coronavirus spike glycoprotein is important for spike-mediated cell fusion
por: Petit, Chad M., et al.
Publicado: (2007) -
Spiked Helmet or Spiked Electrode?
por: Aslanger, Emre, et al.
Publicado: (2021)